|
|
|
BOTA - Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals, Inc. (BOTA) was a publicly-traded biopharmaceutical company that focused on the discovery and development of antiviral drugs to treat respiratory diseases. The company was founded in 2003 and was headquartered in Atlanta, Georgia.
However, as of 2016, BOTA merged with Nabriva Therapeutics plc and is no longer a publicly-traded company. Prior to the merger, the company was primarily focused on the development of its lead drug candidate, laninamivir octanoate, which was an investigational treatment for influenza.
Investing in biopharmaceutical companies like BOTA carries certain risks, including the potential for market fluctuations, regulatory risks, and clinical trial risks. Additionally, the success of a company's therapies is dependent on several factors, including the safety and efficacy of the products and the ability to obtain regulatory approval. Potential investors should carefully consider these risks before making any investment decisions.
|
|
|
|
|
